Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase NA 3Phase 1 2Phase 2/3 1Phase 1/2 1

Status

Completed 3Withdrawn 1Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1Dermatologic 1

Conditions

Precancerous Conditions 1Keratosis, Actinic 1

Interventions

Oxaliplatin 5Leucovorin 5Fluorouracil 5Gemcitabine 4pirarubicin 2liposomal doxorubicin 2Surgical Procedures, Operative 2Radiation 2Paclitaxel 2Neoadjuvant Therapy 2Folfox protocol 2Capecitabine 22-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 2vocimagene amiretrorepvec 1taxane 1sulindac sulfone 1remdesivir 1pembrolizumab 1nimotuzumab 1methylnaltrexone 1lenvatinib 1irinotecan sucrosofate 1carbon-11 acetate 1bavituximab 1alovudine 1aflibercept 1Thyroxine 1Therapeutics 1Temozolomide 1Taxes 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Withdrawn × Celecoxib × Clear all
NCT00027976 2013-08-05

Celecoxib in Preventing Skin Cancer in Patients With Actinic Keratoses

University of Alabama at Birmingham

Phase 2/3 Withdrawn
DermatologicOther neoplasm

Precancerous Conditions, Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡